It has been confirmed that the pathogenesis and progression and heterogeneity of MDS are closely related to the genetic landscape (Maciejewski & Balasubramanian, 2017), such as tet methylcytosine dioxygenase 2 (TET2), isocitrate dehydrogenase1/2 (IDH1/2), additional sex comb-like 1 (ASXL1), enhancer of zeste homolog 2 (EZH2), NRAS proto-oncogene (NRAS), RUNX family transcription factor 1 (RUNX1) and GATA binding protein 2 (GATA2). This evidence concerns the gene NRAS and myelodysplastic syndrome.